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This is a randomized, double-blind, placebo-controlled study comparing the eﬀects of a water extract of Labisia pumila var.
alata at 280mg/day with placebo, given for 6 months in postmenopausal Malay women. There were 29 patients treated with
Labisia pumila and 34 patients in the placebo group. Menopausal symptoms were assessed at baseline and at 6 months. The
blood pressure, body mass index, waist circumference, fasting blood sugar, lipid proﬁle, and hormonal proﬁle (follicle stimulating
hormone/luteinizing hormone/estradiol) were measured during visits every two months. ANCOVA model analysis showed
signiﬁcantly lower triglycerides levels in LP subjects at 6 months after treatment as compared to placebo (1.4 versus 1.9mmol/L;
adj. mean diﬀerence 0.5, 95% CI: 0.02, 0.89 after adjusted for the baseline values, age, BMI, and duration of menopause placebo).
Other parameters in both groups did not diﬀer signiﬁcantly. In conclusion, daily intake of Labisia pumila at 280mg/day for six
months was found to provide beneﬁt in reducing the triglyceride (TG) values.
1.Introduction
The number of women entering menopause has increased
worldwide due to the increment of life expectancy. One of
the important issues aﬀecting postmenopausal women is the
risk and beneﬁts of estrogens replacement therapy. Many
of the women who are prescribed hormone replacement
therapy stop taking it or never commence taking it due to
fear of associations with malignancy, unacceptable bleeding,
or its side eﬀects. Instead, they search for alternative ways
of self-managing the postmenopausal symptoms or its long
term consequences, such as increased risk of coronary artery
disease (CAD) and osteoporosis.
Labisia pumila (LP) or more commonly known as
Kacip Fatimah has been used widely in South East Asian
communities for a variety of illnesses and in food sup-
plements. This plant has been widely used by Malaysian
women for generations to ease childbirth and also for its
postpartum rejuvenating properties [1]. Traditionally, LP
extract is prepared by boiling the roots, leaves, or the whole
plant in water, and the extract is consumed orally [1]. Its
exclusive use by women has led to the belief that it is a
phytoestrogen, a compound with similar chemical structures
to estrogen [2], and is therefore able to relieve menopausal
symptoms [3].
L. pumila is from the genus Myrsinaceae. Three diﬀerent
varieties of L. pumila were identiﬁed in Malaysia: var.a l a t a ,
var. pumila,a n dv a r .lanceolata [4]. The term Kacip Fatimah
is used to describe the plant in general. Preliminary studies
have shown that the var. alata and var. pumila are more
commonly used medicinal plants than var. lanceolata.
PhytochemicalstudiesoftherootsandleavesofL.pumila
var. alata have shown the presence of three C15 monoene2 Evidence-Based Complementary and Alternative Medicine
resorcinols that are (Z)-5-(pentadec-4-enyl) benzene-1-
3,3-diol, (Z)-5-5-(pentadec-8-enyl) benzene-1-3,3-diol, and
(Z)-5-5-(pentadec-10-enyl) benzene-1-3,3-diol [5]. In addi-
tion, it also contains two novel benzoquinoid compounds 1,
2 as major components [6].
Research has demonstrated the estrogenic activity of
LP. It is possible that it acts as selective estrogen receptor
modulators (SERMs) which is active in certain tissues,
[7]. A study showed that water extracts of LP were able
to displace estradiol binding to antibodies raised against
estradiol, making it similar to other estrogens such as estrone
and estradiol [7]. The extract has also been found to produce
a dose-response eﬀect on the reproductive hormones of
female rats, notably on the estradiol and free testosterone
levels [7].
Recently, study has showed that Labisia pumila (LP) is a
potential alternative agent for hormone replacement therapy
in postmenopausal women [8]. In that study, a group of
researchers [8] had conducted a study comparing the
eﬀect of LP aqueous extract to estrogen on reproductive
hormones using ovariectomised rat model. Labisia pumila
supplementation had been shown to resemble the eﬀect
of estrogen replacement therapy on reproductive hormones
[8]. In the study, it showed that 60-day treatment with LP
signiﬁcantly reduced luteinizing hormone (LH) and follicle
stimulating hormone (FSH). It also elevates the estradiol
and testosterone levels. These results resembled the eﬀect of
estrogen in the ovariectomised rats.
Currently, L. pumila is manufactured in the form of
tonics or capsules by local companies, and various claims
have been made that L. pumila can improve the well-being of
women. It is imperative that all these declarations regarding
the beneﬁts and advantages of L. pumila or any herbal
formulations containing L. pumila are proven scientiﬁcally,
and that any possible toxicity arising from its consumption is
evaluated.
In view of the initial evidence, it is postulated that this
plant has a beneﬁcial eﬀect on postmenopausal women in
terms of the positive impact on the lipids and hormonal
proﬁles. The present study was designed to investigate the
eﬀect of LP on menopausal symptoms, cardiovascular risk
factors, and hormonal proﬁles in Malay postmenopausal
women.
2.MaterialsandMethods
2.1. Study Design and Setting. This randomised, parallel-
group, placebo-controlled study to compare the eﬀects of
Labisia pumila var. alata extract at 280mg/day was carried
out amongst postmenopausal Malay women at the Clinical
Trial Unit, Hospital Universiti Sains Malaysia (HUSM) from
June 2004 until May 2005.
2.2. Study Participants. Malay women aged between 48 to
55 years with the body mass index ranging from 18 to
35kg/m2 were eligible for the study if they had been post-
menopausal for at least six months. The women were not
assessed on whether they had any menopause symptoms.
The exclusion criteria included a history of taking hormone
replacement therapy or any herbal products for at least 6
months, a history of oophorectomy, a history of alcohol
or drug abuse, a history of breast or cervical cancer, any
active medical illnesses making the implementation of the
study protocol or interpretation of the results diﬃcult, or
the presence of endometrium thickness of more than 0.5cm
detected with a pelvic ultrasonography.
The study participants were identiﬁed from the Obstet-
rics & Gynaecology Clinic or from the outpatients’ clinic of
HUSM. They were invited to come to the Clinical Trial Unit
forthestudyexplanationandscreeningprocedure.Informed
consent was obtained once they agreed to participate in the
study. A detailed history including past medical history and
gynaecology history was assessed at baseline. The physical
examination including blood pressure, weight, height, and
waist hip ratio measurement, and cardiovascular, breast,
abdomen, and pelvic examinations including Pap smear and
pelvic ultrasound were performed at the initial and the last
visit.
2.3. Randomization and Interventions. Study participants
were randomly allocated to either LP or placebo by means
of computer-generated randomization numbers issued by
the Institute for Medical Research (IMR). Subject eligibility
was established before treatment randomization which was
done after the baseline visit and after the patient agreed to
participate and signed the informed consent. The research
nurse determined the treatment allocation by drawing a
sealed nonopaque envelope containing instructions on the
treatment allocations.
2.4. Plant Material. The raw material of Labisia pumila var.
alata was identiﬁed and authenticated by ethno botanist
of the Forest Research Institute of Malaysia (FRIM). The
preparation of water extract of Labisia pumila var. alata
is done by subjecting the dried plant material to water
to form a water-soluble extract and then desiccating the
extract. The process for preparation of Labisia pumila extract
is by extracting dried Labisia pumila plant material with
water at a ratio of 1:6 of dried Labisia pumila plant
material:water to form a water-soluble extract and drying
the extract wherein the extracting is carried out at 80◦Cf o r
3 hours and with continuous stirring. The starting material
is fully dehydrated by drying it at 40◦C for three days. The
process wherein the extracting is repeated and the ratio
of Labisia pumila plant material:water is 1:6. Then the
Labisia pumila extract is dried by spray drying and wherein
the spray drying comprises concentrating and drying. The
spray drying is performed using a spray tower having a
tower inlet and outlet, wherein tower inlet temperature is
185◦C, and wherein tower outlet temperature is 107◦C,
respectively.Thenaprocessforisolatingamarkercompound
by semipreparative reverse-phase high-performance liquid
chromatography was done from Labisia pumila extract. The
marker compound is 3,4,5-trihydroxybenzoic acid.
The extract that was used in this study was similar with
most of the animal studies [7–10] conducted since it was a
big research project planned by the Malaysia government
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Technology and Innovation (MOSTI). Labisia pumila var.
alata extract was prepared and packed in a sachet form
by a Good Manufacturing Practice (GMP) certiﬁed herbal
company that has been approved by the Drug Control
Authority, Ministry of Health, Malaysia.
2.5. Dosage and Study Protocol. The dosage used was based
on animal studies carried out by the Institute for Medical
Research Malaysia (IMR). Based on the study, a signiﬁcant
response in estradiol and testosterone levels were seen when
the rats received 16mg/kg body weight ofL. pumila var. alata
extract. Using the conversion dose as suggested by Freireich
et al. [11] where the dose conversion used was 1/7 of rat
dose equals to a 60kg man dose, the minimum dose of L.
pumila var. alata extract to be tested was 140mg. In this
study, we used the double dose of the minimum dose needed
because we did not know the dose that will give signiﬁcant
response in human. Due to budget constraint to do study for
all three doses that is 140mg, 280, or 560mg, we decided to
use 280mg of L. Pumila extract per day for this study.
The study subjects were required to take two sachets
of the extract of L. Pumila daily at night for six months.
The compliance was measured using the numbers of sachets
taken.Thesachetsweresuppliedtothepatientseverymonth,
and subjects were asked to return all unused medication.
The number of sachets issued minus the number of sachets
returned was used to calculate the compliance.
2.6. Outcome Measures and Followups. The women were
given questionnaires to assess their menopausal symptoms.
This questionnaire was validated and based on previous
study [12]. It consisted of a list of symptoms which com-
prised of classical vasomotor symptoms, physical symptoms,
and psychological symptoms. Each of the symptoms was
assessed using the Likert scale from 0 to 5. They were asked
to ﬁll in this questionnaire at baseline and at the end of
six months. Blood samples to measure fasting glucose levels,
total cholesterol, low density lipoprotein (LDL), high density
lipoprotein (HDL), triglycerides, luteinizing hormone (LH),
follicle stimulating hormone (FSH), and estradiol levels as
study outcomes were taken at baselines and at two-month
intervals. The subjects were followed up every two months
for the total duration of six months. At each visit, the
subjects were examined by medical specialists who were part
of the clinical trial team, and they were asked for feedback
regarding any side eﬀects.
2.7. Approval by the Research and Ethics Committee. Ethical
approval was obtained from the Research and Ethics Com-
mittee, Universiti Sains Malaysia prior to the study imple-
mentation. The protocol was approved by the Research and
Ethical Committee, School of Medical Sciences, University
Sains Malaysia (USM/PPSP/Ethics Com./2004 (125.4(6)).
2.8. Statistical Analyses. Analyses were done by using SPSS
for windows version 12.0, and all numerical variables were
expressed as mean and standard deviation (SD) and categor-
ical data as frequencies and percentages. Randomized groups
were compared for any possible diﬀerences at baseline using
independentt-andchi-squaretests.Toshowtheeﬀectiveness
of the treatment group, analysis of covariance (ANCOVA)
was used to compare the diﬀerence of the outcome variables
at 6-month postintervention after controlling the age, BMI,
duration of menopause, and the baseline values as the
covariates. Summary changes were reported as means, stan-
dardizing changes for possible covariate imbalances between
groups. All reported P values are 2-tailed with a value of less
than 0.05 which is considered signiﬁcant.
3. Results
A total of 63 patients completed the 6-month study. The
baseline characteristic of the study participants is shown
in Table 1. There were no statistical signiﬁcant diﬀerences
between the treatment group and placebo at baseline in
terms of age, duration of menopause, parity, clinical, bio-
chemical, and hormonal parameters.
3.1. Table 2. It displays the mean of the menopausal symp-
toms scores of both groups comparing the baseline and
the last visit. Both groups showed a reduced trend within
the groups. However, there was no signiﬁcant diﬀerence
observed between the placebo and the verum (treatment)
group.
3.2. Table 3. It shows the cardiovascular risk factors and hor-
monal changes after the 6-month followup trial with placebo
and LP at 280mg. After adjustments were made regarding
age, BMI, duration of menopause, and its baseline values,
there was a signiﬁcant main eﬀect of treatment on the TG
levels [F(1,63) = 4.309, P = 0.042, ANCOVA] where
the adjusted mean of TG in LP subjects was signiﬁcantly
lower than placebo (1.4 versus 1.9mmol/L) (adj. mean
diﬀerence 0.5, 95% CI: 0.02, 0.89) (Table 3). There were also
comparatively lower means of the fasting plasma glucose and
total cholesterol in the LP treatment group; however, the
diﬀerences were not statistically signiﬁcant.
4. Discussion
Previously, hormone replacement therapy has subsisted
as the mainstay of treatment for problems arising from
loss of ovarian functions. However, recent studies have
c h a n g e dt h i sp r a c t i c ed u et oa d v e r s ee ﬀects as regards to
hormone replacement therapy (HRT) [13]. Now, there are
many controversial issues regarding prescribing HRT for
postmenopausal women. These is a cause for the tremen-
dous growth in the use of alternative therapies to relieve
the postmenopausal symptoms. Many women assume that
alternative medicine is safe and natural. However, compared
to HRT, there are still not suﬃcient clinical trials to assess
the eﬀect of phytoestrogen on cardiovascular risk factors and
osteoporosis evidenced by changes in bone mineral density.
There is still very little information about Labisia pumila
var. alata chemical properties and the mechanism of action
despite its wide range of use among females in Malaysia.
The plant root and leaves were found to contain two novel
benzoquinoid compounds 1, 2 as major components [6].4 Evidence-Based Complementary and Alternative Medicine
Table 1: Baseline characteristics among participants of randomized controlled trial between Labisia pumila and placebo groups.
Characteristics All∗ (n = 63)
Trial groups∗
P value‡
Labisia
(n = 29)
Placebo
(n = 34)
Age (years) 52.7 (1.9) 52.9 (1.8) 52.6 (1.9) 0.445
Age at menarche (years) 13.9 (1.7) 13.9 (1.7) 13.9 (1.7) 0.790
Duration of menopause (years) 3.2 (3.1) 3.0 (2.9) 3.6 (3.2) 0.495
Number of parity (%)†
<5 23 (36.5) 8 (27.6) 15 (44.1) 0.174
≥5 40 (63.5) 21 (72.4) 19 (55.9)
Household income per month (%)†
≤RM 1,000 39 (61.9) 19 (65.5) 20 (58.8) 0.586
>RM 1,000 24 (38.1) 10 (34.5) 14 (41.2)
Body mass index (BMI) (kg/m2) 26.5 (3.7) 26.4 (4.5) 26.5 (3.1) 0.814
Waist hip ratio 0.85 (0.08) 0.85 (0.08) 0.86 (0.09) 0.812
Diastolic BP (mmHg) 82.9 (10.1) 81.8 (10.5) 83.8 (9.9) 0.439
Systolic BP (mmHg) 125.3 (18.5) 122.8 (18.5) 127.3 (18.4) 0.339
Total cholesterol (mmol/L) 5.2 (1.1) 5.1 (1.1) 5.3 (1.1) 0.601
Triglycerides (mmol/L) 1.7 (1.4) 1.4 (1.1) 1.9 (1.6) 0.095
Fasting glucose (mmol/L) 6.1 (1.9) 5.8 (0.7) 6.2 (2.6) 0.433
Female hormones (IU)
FSH 49.0 (22.2) 45.8 (23.7) 51.8 (20.8) 0.297
LH 23.6 (13.6) 23.8 (14.8) 23.3 (12.6) 0.877
Estrogen 38.7 (19.0) 35.7 (12.2) 41.2 (22.9) 0.271
∗Values are expressed as mean (standard deviation, SD) unless otherwise speciﬁed.
‡Determined by independent t-test; †chi-square tests.
Another group of researcher had conducted a study which
looked at the adverse eﬀects of the aqueous extract of
this plant on the oestrous cycle, reproductive performance,
postnatal growth, and the oﬀsprings of rats [9]. In that
study, the water-based extracts did not pose any signiﬁcant
reproductive toxicity or complication during pregnancy and
delivery in rats. Currently, to our knowledge, the toxicology
studies were done only in rats.
Theoretically, phytoestrogens exert their eﬀects primarily
through binding to estrogen receptors (ERs) [14]. Reports
have shown that the plant displays a nonsigniﬁcant response
to in vitro estrogen activity [5]. The water extract of LP was
shown to be able to displace estradiol binding to antibodies
raised against estradiol making it similar to other estrogens
suchas estrone and estradiol [7].The extractalso produced a
dose response eﬀect on the reproductive hormones of female
rats, notably on estradiol and free testosterone levels [7].
However, in this study, there was no eﬀect of LP on the
menopausal symptoms and hormonal proﬁles in the post
menopausal women. The possible explanations are that the
sample size in this study is very small, and also it needed to
be given in a longer duration before the eﬀects can be seen.
In animal study, it showed that estrogen replacement therapy
increased estradiol level as early as 30 days of treatment
c o m p a r e dt oL Pw h i c hr e q u i r e s6 0d a y so ft r e a t m e n t[ 8].
There were few limitations in this study. Although
the treatment group showed reduced triglyceride levels
compared to the placebo group, however the level in both
groups was still within the normal range. Therefore, it is of
no clinical relevance at this moment. We suggest that further
study is required in order to assess this eﬀect. In an animal
study, it was revealed that the ovariectomised rats treated
with LP extract had decreased in body weight compared to
the control group and have postulated that this mechanism
occurred due to the presence of phytoestrogen in it [10].
The study postulates that there is a possible role for Labisia
pumila var. alata in modulating postmenopause adiposity in
a manner similar to that reported for estrogen through the
initiation of the lipolysis process in adipose tissue and thus
may have a possible eﬀect on weight management [10].
Intheotherstudy[15],whichlookedattheeﬀectofwater
extract from Labisia pumila on the aorta of ovariectomized
rats, it was found that the elastic lamellae architecture of
the ovariectomized rat aortae in the treatment group by the
plant was maintained in a manner comparable to the normal
rat. This result implied that there is a possible role for LP in
modulating postmenopausal cardiovascular risks.
This study involved a small sample size which may have
hadanimpactonwhysomeoftheresultsmightnotbesignif-
icant. Conducting a bigger study is highly recommended inEvidence-Based Complementary and Alternative Medicine 5
Table 2: The menopausal symptoms changes after 6-month followup trial with placebo and Labisia pumila.
Menopausal symptoms
∗Placebo
(n = 34)
∗Labisia
(n = 29) P value‡
Hot ﬂushes V1 0.96 (1.34) V1 1.10 (1.32) 0.75
V2 0.56 (0.93) V2 0.90 (1.49)
Night sweats V1 1.04 (1.43) V1 1.24 (1.30) 0.49
V2 0.59 (1.04) V2 0.79 (1.17)
Insomnia V1 1.56 (1.60) V1 1.31 (1.58) 0.78
V2 0.89 (1.15) V2 0.90 (1.34)
Dyspareunia V1 1.89 (1.91) V1 1.72 (1.62) 0.93
V2 1.37 (1.49) V2 1.59 (1.66)
Painful joints V1 2.56 (1.72) V1 2.66 (1.57) 0.63
V2 1.33 (1.44) V2 2.03 (1.38)
Mastalgia V1 0.56 (1.25) V1 0.17 (0.38) 0.52
V2 0.19 (0.48) V2 0.21 (0.62)
Palpitation V1 1.48 (1.55) V1 0.86 (1.56) 0.19
V2 0.52 (0.80) V2 0.55 (0.95)
Irritability V1 2.15 (1.59) V1 2.34 (1.54) 0.34
V2 1.07 (1.17) V2 1.54 (1.21)
Diﬃculty in concentration V1 1.26 (1.58) V1 2.07 (1.41) 0.16
V2 1.15 (1.17) V2 1.79 (1.37)
Memory problem V1 1.89 (1.50) V1 2.07 (1.41) 0.52
V2 1.15 (1.17) V2 1.79 (1.37)
Lethargic V1 2.04 (1.69) V1 1.59 (1.59) 0.75
V2 0.96 (1.29) V2 0.97 (1.05)
∗Values are expressed as mean (standard deviation, SD) unless otherwise speciﬁed.
‡Determined by independent t-test; †chi-square tests.
Table 3: Cardiovascular risk factors and hormonal changes after 6-month followup trial with placebo and Labisia pumila at 280mg.
Study variables
Trial groups†
P value‡
Placebo (n = 34) Labisia (n = 29) Adjusted mean
diﬀerence (95% CI)
Cardiovascular disease risk factors
Total cholesterol (mmol/L) 5.5 (5.2, 5.9) 5.0 (4.6, 5.4) 0.5 (−0.06, 1.04) 0.082
Triglycerides (mmol/L) 1.9 (1.6, 2.2) 1.4 (1.1, 1.7) 0.5 (0.02, 0.89) 0.042
Fasting glucose (mmol/L) 6.3 (5.8, 6.8) 5.6 (5.1, 6.2) 0.7 (−0.06, 1.38) 0.073
Diastolic BP (mmHg) 81.2 (78.3, 84.1) 82.1 (78.9, 85.2) 0.9 (−3.4, 5.2) 0.686
Systolic BP (mmHg) 125.8 (120.9, 130.7) 127.5 (122.1, 132.8) 1.7 (−5.6, 9.0) 0.643
Female hormones (IU)
FSH 36.3 (29.7, 42.8) 38.4 (31.3, 45.5) 2.11 (−7.62, 11.84) 0.665
LH 26.2 (21.8, 30.5) 24.4 (19.9, 29.0) 1.75 (−4.59, 8.08) 0.583
Estrogen 37.5 (31.4, 43.5) 33.5 (26.7, 40.3) 3.94 (−5.23, 13.10) 0.393
Abbreviations: LH: luteinizing hormone; FSH: follicle stimulating hormone; BP: blood pressure.
†Values at 6-month followup are expressed as adjusted means (95% conﬁdence interval, CI) and are adjusted for baseline values, age, BMI, and duration of
menopause.
‡Determined by analysis of covariance (ANCOVA); P value < 0.05 is considered signiﬁcant.6 Evidence-Based Complementary and Alternative Medicine
order to look at the cardiovascular eﬀect of LP and probably
its weight reduction eﬀect.
In conclusion, the result showed that Labisia pumila has
beneﬁcial eﬀect to reduce the triglyceride (TG) values. Thus,
it may be a useful phytosupplement for maintaining cardio-
vascular health in menopausal women. However, there was
no eﬀect on the hormonal proﬁles.
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